HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 321 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $746,690 | +25.6% | 19,547 | +18.8% | 0.00% | 0.0% |
Q2 2023 | $594,734 | +25.8% | 16,457 | +32.2% | 0.00% | 0.0% |
Q1 2023 | $472,897 | -74.5% | 12,449 | -61.8% | 0.00% | -75.0% |
Q4 2022 | $1,854,211 | +56.7% | 32,616 | +9.0% | 0.00% | +33.3% |
Q3 2022 | $1,183,000 | -33.3% | 29,924 | -25.7% | 0.00% | -25.0% |
Q2 2022 | $1,774,000 | +216.8% | 40,300 | +185.3% | 0.00% | +300.0% |
Q1 2022 | $560,000 | -10.5% | 14,125 | -9.4% | 0.00% | 0.0% |
Q4 2021 | $626,000 | -41.4% | 15,589 | -40.6% | 0.00% | -50.0% |
Q3 2021 | $1,068,000 | +71.4% | 26,263 | +92.2% | 0.00% | +100.0% |
Q2 2021 | $623,000 | +12.5% | 13,662 | +3.5% | 0.00% | 0.0% |
Q1 2021 | $554,000 | -78.4% | 13,202 | -78.0% | 0.00% | -85.7% |
Q4 2020 | $2,569,000 | +801.4% | 60,125 | +459.1% | 0.01% | +600.0% |
Q3 2020 | $285,000 | -15.2% | 10,754 | -14.4% | 0.00% | 0.0% |
Q2 2020 | $336,000 | +127.0% | 12,557 | +53.2% | 0.00% | 0.0% |
Q1 2020 | $148,000 | – | 8,199 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 7,048,282 | $126,799,000 | 27.23% |
First Light Asset Management, LLC | 1,630,591 | $29,334,000 | 5.01% |
SNYDER CAPITAL MANAGEMENT L P | 3,393,057 | $61,041,000 | 3.48% |
Bellevue Group AG | 7,663,956 | $137,874,000 | 2.67% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 307,633 | $5,531,000 | 2.52% |
Lombard Odier Asset Management (Switzerland) SA | 900,000 | $16,191,000 | 2.17% |
Elk Creek Partners, LLC | 654,362 | $11,772,000 | 2.02% |
DOHENY ASSET MANAGEMENT /CA | 127,110 | $2,254,000 | 1.79% |
Granite Investment Partners, LLC | 1,277,438 | $22,981,000 | 1.49% |
Amia Capital LLP | 69,409 | $1,249,000 | 1.11% |